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Abstract
The V-ATPase is a highly conserved enzymatic complex that ensures appropriate levels of organelle acidifica-
tion in virtually all eukaryotic cells. While the general mechanisms of this proton pump have been well studied,
little is known about the specific regulations of neuronal V-ATPase. Here, we studied CG31030, a previously
uncharacterized Drosophila protein predicted from its sequence homology to be part of the V-ATPase family.
In contrast to its ortholog ATP6AP1/VhaAC45 which is ubiquitous, we observed that CG31030 expression is
apparently restricted to all neurons, and using CRISPR/Cas9-mediated gene tagging, that it is mainly ad-
dressed to synaptic terminals. In addition, we observed that CG31030 is essential for fly survival and that this
protein co-immunoprecipitates with identified V-ATPase subunits, and in particular ATP6AP2. Using a geneti-
cally-encoded pH probe (VMAT-pHluorin) and electrophysiological recordings at the larval neuromuscular junc-
tion, we show that CG31030 knock-down induces a major defect in synaptic vesicle acidification and a
decrease in quantal size, which is the amplitude of the postsynaptic response to the release of a single synap-
tic vesicle. These defects were associated with severe locomotor impairments. Overall, our data indicate that
CG31030, which we renamed VhaAC45-related protein (VhaAC45RP), is a specific regulator of neuronal V-
ATPase in Drosophila that is required for proper synaptic vesicle acidification and neurotransmitter release.
Key words: ATP6AP1L/ATP6AP1; CG31030/VhaAC45RP; Drosophila melanogaster; neuronal V-ATPase; quantal
size; synaptic vesicle acidification
Significance Statement
In this study, we provide evidence that a previously uncharacterized Drosophila protein, CG31030, is necessary
for fly survival and expressed specifically in neurons, where it interacts with constitutive and accessory subunits of
the V-ATPase. Physiologically, we show that this protein is required for synaptic vesicle acidification and to ensure
proper synaptic transmission at the neuromuscular junction. This implies that CG31030, alias VhaAC45RP, is a
novel synaptic protein essential to nervous system functioning and neurotransmitter release. This work therefore
provides a new step toward a more exhaustive understanding of the regulations of neuronal V-ATPase and their
potential repercussions on synaptic transmission and neurologic diseases.
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Introduction
Many cellular processes require a specific electrochemi-
cal environment for correct functioning, such as posttransla-
tional modifications of proteins in the Golgi apparatus,
lysosomal degradation, endosomal ligand-receptor dissoci-
ation, or hormone concentration (for review, see Forgac,
2007). Eukaryotic cells use a highly conserved proton pump,
called the vacuolar H1-ATPase (V-ATPase), to achieve the
adequate level of acidity in different cellular compartments
(Saroussi and Nelson, 2009). This large enzymatic complex
must be tightly regulated, as it is essential for it to be local-
ized on the right membrane, and to fit the different pH
ranges specific to each organelle and cell type.
In neurons, the V-ATPase plays a crucial role at the syn-
apse, being responsible for acidifying synaptic vesicles
and thus providing the driving force for neurotransmitter
loading (Moriyama et al., 1992). Recently, neuronal V-
ATPase has also gained interest in the context of aging
and neurodegenerative diseases, as its dysregulation,
and resulting impairment of the autophagy-lysosomal
pathway, have been linked to several pathologies such as
Alzheimer’s and Parkinson’s diseases (Colacurcio and
Nixon, 2016; Collins and Forgac, 2020). If the core mech-
anism of the proton pump is now well understood, the
regulations conferring the cell-specific functions of neuro-
nal V-ATPase remain largely unknown, considerably limit-
ing its potential use as a therapeutic target.
The V-ATPase complex is composed of a cytoplasmic
domain (V1) and a membrane-bound domain (V0). The V1
domain contains the catalytic unit responsible for ATP hy-
drolysis. The energy resulting from this reaction powers a
rotational molecular motor spanning from V1 to V0, allow-
ing protons to cross membranes through the port con-
tained in V0 (Vasanthakumar and Rubinstein, 2020). The
assembly of V1 to V0 is necessary for the pump to func-
tion, and reversible dissociation of the two domains has
been shown to occur as a way to regulate V-ATPase
activity (Collins and Forgac, 2020). Though the core mecha-
nism stays the same, one V-ATPase can differ from another
by its composition. In vertebrates, as well as in Drosophila,
V0 is made of five subunits (a, c, c’’, d, and e), while V1 con-
tains eight subunits (A–H; Allan et al., 2005). Each subunit
can have several paralogs encoded by different genes,
and each gene can produce several isoforms, allow-
ing many different possible combinations to form the
full V-ATPase complex. These differences of compo-
sition can also have regulatory effects on the com-
plex, both on its localization and on its functional
properties (Vasanthakumar and Rubinstein, 2020).
The V-ATPase can also be regulated by two accessory
subunits, ATP6AP1/Ac45 and ATP6AP2/PRR (Jansen and
Martens, 2012). Both proteins are found in the nervous tissue
but are also required in other organs, and their mutations
have been linked to cognitive impairments as well as sys-
temic symptoms like immunodeficiency or hepatopathy
(Jansen et al., 2016; Cannata Serio et al., 2018). These two
subunits interact directly with the V0 domain and are believed
to promote assembly of the membrane and soluble regions
of the V-ATPase complex (Abbas et al., 2020). In addition,
two homologs of ATP6AP1 have been described. The first
one, called AC45-like protein (AC45LP), was identified in
Xenopus where, unlike the ubiquitous AC45/ATP6AP1, it is
expressed specifically in kidney and lung (Jansen et al.,
2010). The second one, called ATP6AP1-like (ATP6AP1L) or
Ac45-related protein (Ac45RP), was recently functionally
characterized in mice where it also shows tissue-specificity,
its expression being restricted to neurons (Jansen et al.,
2021). These studies suggest that the AC45 family is larger
than initially expected, and might play an important role in the
tissue-specificity of the V-ATPase complex. Drosophila pos-
sesses identified orthologs of vertebrate ATP6AP1/Ac45 and
ATP6AP2/PRR, named VhaAC45 and ATP6AP2, respec-
tively. These proteins also seem to contribute to assembly of
the V-ATPase in fly tissues (Schoonderwoert and Martens,
2002a; Guida et al., 2018).
In this study, we examined the localization and function
of CG31030, a novel Drosophila ortholog of both
ATP6AP1/Ac45 and ATP6AP1L/Ac45RP, whose charac-
teristic is to be expressed selectively and ubiquitously in
neurons. Whereas a complete deficiency of this protein is
lethal, we found that partial CG31030 knock-down in larv-
al motoneurons impaired synaptic vesicle acidification,
reduced quantal size, which is the amplitude of the post-
synaptic response to the release of a single synaptic vesi-
cle, and induced severe locomotion defects. We also
report that CG31030 from brain tissue co-immunoprecipi-
tated with V-ATPase subunits of the V0 domain. Overall,
our results indicate that CG31030 is a novel accessory
subunit of the neuronal V-ATPase that appears to be in-
volved in the regulation of synaptic activity.
Materials and Methods
Drosophila culture and strains
Flies were raised on standard agar-cornmeal-yeast me-
dium, at 25°C in a 12/12 h light/dark cycle. CG31030
RNAi strains and mutants were obtained from the
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Bloomington Drosophila stock center (BDSC) and the
Vienna Drosophila Resource Center (VDRC). Detailed
genotypes and references of these lines are provided
in Table 1. To construct the UAS-CG31030 strain, the
CG31030 cDNA was PCR amplified from the clone RH09162
obtained from the Drosophila Genomics Resource Center,
using the following primers with added restriction sites: P1-
EcoRI (forward) 59-CCATCCGAATTCAAAATGCAGCTGATT
CTCGT and P2-XhoI (reverse) 59-TGGCTGCTCGAGATC
TATTGGGTTATGAGAGA. The 1160-bp PCR fragment was
inserted into pUAST (Brand and Perrimon, 1993), verified by
sequencing (GATC Biotech) and sent to BestGene, for P-ele-
ment transformation by random insertion in w1118 back-
ground. A 2d-chromosome insertion of UAS-CG31030 that
yielded strong expression of the transgene was used
thereafter.
Reverse transcription-coupled PCR and qPCR
Total RNAs were extracted from 20 heads (or 15
thoraces or 15 abdomens) of 8-d-old flies using the
QIAzol Lysis reagent (QIAGEN). The Maxima First
Strand cDNA Synthesis kit (Thermo Fisher Scientific,
K1671) was used with oligo(dT)20 primers to synthe-
size the cDNAs. Relative quantitative PCR assays were
conducted using a LightCycler 480 and the SYBR
Green I Master mix (Roche LifeScience), with Act5C as
internal control for normalization of mRNA levels. All
reactions were performed in triplicate. The specificity
of amplification products was assessed by melting
curve analyses. The following forward and reverse pri-
mers, were used: for CG31030, 59-GGCTTCGTTGT
AGGCCAACAGA and 59-CACCAGGTATCCCAAGTT
CCAGA; for Act5C, 59-CGTCGACCATGAAGATCAAG
and 59-TTGGAGATCCACATCTGCTG; for ATP6AP2,
59-ACGATCCCTTCAACCTGGC and 59-CCTGTCAGC
TCGTAGGTCT; for VhaAC45, 59-TGTCCCAAGTGG
AGTTTGCC and 59-TCAGGCCATTTTCCTCGAAGG;
for Vha100-1, 59-GGCATCCCCATGTTGGACA and 59-
CGGCGTTCTGATTCACCTCC; for VhaAC39-1, 59-GC
AGGCTGACTATCTCAACCT and 59-GCTCCACAGCAT
GGTTCCTC; for Vha16-1, 59-AAGTCTGGTACCGGTA
TTGC and 59-CCATGACCACAGGAATGATG. PCR as-
says were performed using the PrimeStar Max DNA
polymerase (Takara) and the following primers: for
CG31030-RA/RB, 59- TGAGGTGTACGACTGCATAGGA
and 59- GAAAGAACTCGATGGCCAAGGT; for CG31030-
RA, 59-CAAGGGATACGGTCGATTGAGCATCAC and 59-
CTTACTCCTGTACGGTGAAGGTCAAC; for CG31030-RB,
59- CAAGGGATACGGTCGATTGAGCATCAC and 59-
ATGAACATGGCTGCCCGAGATTGTTTGCT.
Protein extraction andWestern blotting
A total of 30 Drosophila heads were homogenized in
300-ml RIPA buffer (Sigma-Aldrich) containing protease in-
hibitors (Roche Diagnostics, Complete Protease Inhibitor,
Cocktail), using bead tubes and a Minilys apparatus (Bertin
Technologies). Proteins samples and Western blotting were
processed as previously described (Issa et al., 2018). Briefly,
the extracted proteins were mixed with LDS sample buffer
and reducing agent (Invitrogen, NuPAGE), heated at 70°C for
5min and separated in 4–12% Novex NuPAGE Bis-Tris pre-
cast polyacrylamide gels (Life Technologies) following the
Table 1: Drosophila strains used in this study
Name Genotype Usage Sources References





In-house construct This report
CG31030V5 w; CG31030V5 Insertion of a V5 tag in
CG31030
In-house construct This report
CG31030RNAi1 y, sc, v, sev21; P{y1t7.7
v1t1.8=TRiP.HMC05568}
attP40
CG31030 knock-down BDSC no. 64549 Perkins et al. (2015)
CG31030RNAi2 y, w1118 ; P{KK106825}VIE-
260B
CG31030 knock-down VDRC no. 107398 Dietzl et al. (2007)
CG31030RNAi3 w1118; P{GD381}v33095/TM3 CG31030 knock-down VDRC no. 33095 Dietzl et al. (2007)
CG31030MI107 y, w; Mi{y1mDint2=MIC}
CG31030MI00107/TM3, Sb,
Ser
MIMIC CG31030 mutant BDSC lno. 30620 Nagarkar-Jaiswal et
al. (2015)




and ;20 other genes
BDSC no. 7692 Parks et al. (2004)














w; VmatUAS.pHluorin Expression of Drosophila
Vmat fused to the pH-sen-
sitive fluorescent marker
ecliptic pHluorin
Gift of David Krantz,
University of California,
Los Angeles
Wu et al. (2013)
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manufacturer’s protocol in a MOPS-SDS running buffer. A
semi-dry transfer was done onto polyvinylidene difluoride
membranes (GE Healthcare Hybond P 0.45mm) using a
Hoefer TE77 apparatus. The mouse monoclonal anti-
V5 (Thermo Fisher Scientific, R960-25) was used, di-
luted at 1:500. Immunolabeled bands were revealed
by ECL RevelBlOt Intense (Ozyme, OZYB002-1000)
as chemiluminescent HRP substrate and digitally acquired
using the ImageQuant TL software (GE Healthcare Life
Science).
CRISPR/Cas9 gene tagging
The sequence of a V5 tag was inserted in frame after the
coding sequence of the CG31030 gene, using a homol-
ogy-directed repair CRISPR-Cas9 method (see scheme
in Fig. 1D). The following guide RNA sequence: 59-
TTCACCGTACAGGAGTAAGG-39 was cloned into the
BbsI site of pCFD3-U6:3-gRNA plasmid (Port et al.,
2014; kind gift of Hervé Tricoire, Université de Paris, Paris,
France). This plasmid was then injected, at a concentration of
500ng/ml, with the following single-stranded oligodeoxynu-




TAGATCTCGGGC-39 (synthetized by Integrated DNA
Technology), also at a concentration of 500ng/ml (the se-
quence underlined corresponds to the in-frame V5 tag),
into nos-cas9 embryos [genotype y1, P(nos-cas9, w1), M
(3xP3-RFP.attP)ZH-2A, w*; Port et al., 2014]. An alanine
was added before the V5 tag to prevent the creation of
a potential tyrosine phosphorylation site. Embryo injec-
tions were performed by BestGene. Single F0 flies were
crossed over the TM6C(Sb) balancer to establish stable
lines. DNA was then extracted from three flies of each
of these independent lines, and V5 insertion events
were detected by dot blot using a mouse anti-V5 tag
monoclonal antibody (Thermo Fisher Scientific, R960-
25). Positive strains were outcrossed in a w1118 back-
ground and their genomic DNA was sequenced to
check for proper in-frame V5 integration in CG31030.
One of these equivalent CG31030V5 mutant line was
selected for further studies.
Immunohistochemistry
Adult brains of 8-d-old females, or third-instar larva
CNS, were dissected in Drosophila Ringer’s solution or
hemolymph-like saline solution (HL3; 70 mM NaCl, 5 mM
KCl, 1.5 mM CaCl2, 70 mM MgCl2, 10 mM NaHCO3, 115
mM sucrose, 5 mM trehalose, and 5 mM HEPES, with pH
adjusted to 7.6), respectively, and fixed in 4% paraformal-
dehyde (Thermo Fischer Scientific) for 1 h. After three 20
min washes in PBS plus 0.5% Triton X-100 (PBT), brains
were blocked in PBT1 2% bovine serum albumin for 2 h.
They were then incubated in primary antibodies diluted in
blocking solution for 24 h at 4°C. The primary antibodies
used were: mouse monoclonal anti-V5 (Thermo Fisher
Scientific, R960-25, 1:200) and rat anti-Cadherin-N (CadN;
DSHB, DN-Ex #8, 1:20). Brains were then washed three
times, for 20min each, in PBT before being incubated in
secondary antibodies for 2 h. Secondary antibodies used
were: Alexa Fluor 488 anti-mouse and Alexa Fluor 555 anti-
rat (Fisher Scientific, A11029 and A21434, respectively), all
diluted at 1:1000. After two 20-min washes in PBT followed
by two 20-min washes in PBS, brains were mounted in
Prolong Gold Antifade Mountant (Thermo Fisher Scientific,
P36930). Imaged were acquired on a Nikon A1R confocal
microscope.
For immunostaining of the larval muscles and neuro-
muscular junctions, the Alexa Fluor 488 Tyramide
SuperBoost kit (Thermo Fisher Scientific, B40912) was
used to increase the V5 signal that was otherwise faint
in this tissue. The working protocol was as recom-
mended by the manufacturer, with anti-V5 diluted to
1:100, then followed by classical immunostaining, as
described above, to co-stain for the nerve terminals
with an anti-HRP antibody (Jackson ImmunoResearch,
323-005-021, 1:200) and an anti-Vha100-1 (courtesy
of Dr. Peter Robin Hiesinger, 1:2000).
Longevity assay
Approximately 110 virgin females from each genotype
were collected on their hatching day and placed in clean
bottles, with no more than 25 flies per bottle. Flies were
transferred in new clean bottles, and survivors were
counted, every 2 d for 60d.
Co-immunoprecipitation coupled to nano liquid
chromatography coupled to tandemmass
spectrometry (LC-MS/MS) analysis
Approximately 200 heads from 8-d-old CG31030V5 and
w1118 flies were lysed using glass beads in 500ml of ice-
cold lysis buffer: 50 mM Tris-HCl pH 7.4, 2 mM EDTA, 150
mM NaCl, 0.5% (v/v) IGEPAL CA-630 (Sigma-Aldrich,
I3021), 10% (v/v) glycerol, 1 mM PMSF protease inhibitor
(Sigma-Aldrich, P-7626), and 1 cOmplete Mini Protease
Inhibitor Cocktail (Roche, 11836153001). Samples were
left on ice, with occasional gentle agitation, for 30min be-
fore being centrifuged at 12,000 rpm (13,000  g) at 4°C
for 10min to remove insoluble material; 400ml of the
supernatants were then added to 50ml of Anti-V5-tag
mAb-Magnetic Beads (MBL International, M167-11), that
had been previously washed as recommended by the
manufacturer. Samples were incubated with gentle agita-
tion at 4°C for 4 h. The supernatants were removed using
a magnetic rack, and beads were washed three times
with 500 mM ice-cold lysis buffer before being resus-
pended in 10 ml of milliQ water.
Nano LC-MS/MS was performed at the Proteomics fa-
cility of the Institut Jacques Monod (Université de Paris).
Proteins on beads were digested overnight at 37°C with
trypsin (Promega) in 25 mM NH4HCO3 buffer (0.2mg tryp-
sin in 20ml). The resulting peptides were desalted using
ZipTip m-C18 Pipette Tips (Pierce Biotechnology). Eluates
were analyzed using either an Orbitrap Fusion or an Orbitrap
Q-Exactive Plus, coupled, respectively, to a Nano-LC
Proxeon 1200 or a Nano-LC Proxeon 1000, both equipped
with an easy spray ion source (Thermo Fisher Scientific).
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On the Orbitrap Fusion instrument, peptides were
loaded with an online preconcentration method and sepa-
rated by chromatography using a Pepmap-RSLC C18
column (0.75 750 mm, 2mm, 100Å) from Thermo Fisher
Scientific, equilibrated at 50°C and operated at a flow rate
of 300 nl/min. Peptides were eluted by a gradient of sol-
vent A (H2O, 0.1% FA) and solvent B (ACN/H2O 80/20,
0.1% FA). The column was first equilibrated for 5min with
95% of A, then B was raised to 28% in 105min and to
40% in 15min. Finally, the column was washed with 95%
B during 20min and re-equilibrated at 95% A for 10min.
Peptides masses were analyzed in the Orbitrap cell in full
ion scan mode, at a resolution of 120,000, a mass range
of m/z 350–1550 and an AGC target of 4.105. MS/MS
were performed in the top speed 3s mode. Peptides were
selected for fragmentation by higher-energy C-trap disso-
ciation (HCD) with a normalized collisional energy of 27%
and a dynamic exclusion of 60 s. Fragment masses were
measured in an Ion trap in the rapid mode, with and an
AGC target of 1.104. Monocharged peptides and unas-
signed charge states were excluded from the MS/MS ac-
quisition. The maximum ion accumulation times were set
to 100ms for MS and 35ms for MS/MS acquisitions,
respectively.
On the Q-Exactive Plus instrument, peptides were
loaded with an online preconcentration method and
separated by chromatography using a Pepmap-RSLC
C18 column (0.75 500 mm, 2mm, 100 Å) from Thermo
Scientific, equilibrated at 50°C and operated at a flow
rate of 300 nl/min. Peptides were eluted by a gradient
of solvent A (H2O, 0.1% FA) and solvent B (100% ACN,
0.1% FA), the column was first equilibrated 5min with
95% of A, then B was raised to 35% in 93min and fi-
nally, the column was washed with 80% B during
10min and re-equilibrated at 95% A during 10min.
Peptides masses were analyzed in the Orbitrap cell in
full ion scan mode at a resolution of 70,000 with a
mass range of m/z 375–1500 and an AGC target of
3.106. MS/MS were performed in a Top 20 DDA mode.
Peptides were selected for fragmentation by HCD with
a normalized collisional energy of 27%, and a dynamic
exclusion of 30 s. Fragment masses were measured in
the Orbitrap cell at a resolution of 17,500, with an AGC
target of 2.105. Monocharged peptides and unas-
signed charge states were excluded from the MS/MS
acquisition. The maximum ion accumulation times
were set to 50ms for MS and 45ms for MS/MS acquis-
itions, respectively.
Raw data were processed on Proteome Discoverer 2.4
with the mascot node (Mascot version 2.5.1) against the
Swissprot/TrEMBL protein database release 2019_12 for
Drosophila melanogaster. A maximum of two missed
cleavages was authorized. Precursor and fragment mass
tolerances were set to, respectively, 7 ppm and 0.5Da
(Orbitrap Fusion) and to 6ppm and 0.02Da (Orbitrap Q-
exactive Plus). The following posttranslational modifica-
tions were included as variable: acetyl (protein N-term),
oxidation (M), phosphorylation (STY). Peptide identifica-
tions were validated with a 1% FDR (false discovery rate)
threshold calculated with the Percolator algorithm. Label-
free quantification was done in TOP three abundance cal-
culation mode with pairwise ratio-based calculation and t
test (background based) hypothesis test. Only proteins
identified in at least one group in two independent experi-
ments were kept in the analysis. Missing values were set
to the minimum abundance of the experiment.
VMAT-pHluorin experiments
Third-instar larvae expressing VMAT-pHluorin with or
without CG31030 RNAi in motor neurons using the
OK371-Gal4 driver, were dissected to expose the body
wall muscles in Ca21-free HL3 saline solution (70 mM
NaCl, 5 mM KCl, 70 mM MgCl2, 10 mM NaHCO3, 115 mM
sucrose, 5 mM trehalose, and 5 mM HEPES, pH 7.6). Two
other solutions were used: an acidic Ca21-free HL3 saline
(pH 5.5) and a neutral HL3-NH4Cl saline (pH 7.6), in which
50 mM NaCl was replaced by 50 mM NH4Cl. After dissec-
tion, larvae fillets were allowed to settle in Ca21-free HL3
saline for 10min before being scanned a first time directly
in a drop of the solution using a Nikon A1R confocal mi-
croscope. Ca21-free HL3 saline was then replaced either
by the acidic Ca21-free HL3 saline for low pH-induced
quenching experiments, or by the HL3-NH4Cl saline for
pH gradient collapse experiments. In both cases, larval fil-
lets were rinsed three times with the modified solution,
and incubated for 3min, before being scanned a second
time, in a drop of modified solution. Quantification was
done on Z-projections (set to maximal intensity) of confo-
cal stacks. Using the Fiji software, a fixed threshold was
applied to all images to get rid of the background and se-
lect only synaptic areas. Percentage of area over the
threshold was used as a measure of the signal intensity
and ratios of the values obtained in modified solutions
over standard HL3, i.e., the second scan over the first
scan, were calculated for quantifications.
Larval locomotion assays
Larval locomotion was assessed on an in-house made
version of the FIMtable system (Risse et al., 2014). Third-
instar larvae were collected and briefly rinsed in water to
remove traces of food, before being gently placed on the
recording table precoated with a thin layer of 1.2% agar
gel. Only four larvae of the same genotype were recorded
simultaneously, to avoid collisions between animals, for a
period of 2min with a Basler ace acA2040-25gm camera
at 12.5 frames/s. Larvae that burrowed themselves into
the agar plate or escaped the arena before the end of re-
cording were excluded from the results. Tracking was
done using the FIMtrack software, as described in (Risse
et al., 2014). The number of peristaltic waves was com-
puted from the variations in larval area. More precisely,
the curves of area variation were first smoothed with a
Savitzky–Golay filter to get rid of unwanted noise, then
the number of waves was defined as the number of peaks
on the curve (which was automatically computed by a
custom-made Python script). Stride size was then calcu-
lated as the distance traveled by the larva divided by the
number of peristaltic waves, while stride duration was
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defined as the recording time (i.e., 120 s) divided by the
number of peristaltic waves.
Electrophysiological recordings and quantal analysis
Third-instar larvae expressing CG31030 RNAi in motor
neurons using the OK371-Gal4 driver, and appropriate con-
trols, were dissected to expose the body wall muscles, and
the brain removed, in Ca21-free HL3 saline solution (70 mM
NaCl, 5 mM KCl, 70 mM MgCl2, 10 mM NaHCO3, 115 mM su-
crose, 5 mM trehalose, and 5 mM HEPES, pH 7.6; Stewart et
al., 1994; Cattaert and Birman, 2001). Spontaneous miniature
EPSPs (mEPSPs) were recorded in the presence of tetrodo-
toxin (TTX) 106 M, so that no spike could occur, from the
ventral longitudinal abdominal muscle 6 in segment A3.
Quantal analysis was performed following the theoretical
background described in (Kuno, 1971) and (Castellucci and
Kandel, 1974). Distribution histograms of mEPSP size were
built from each muscle fiber recording with a 0.01-mV bin
size. These histograms provided an estimate of the mean
size of a unitary EPSP, since the peaks represent integer mul-
tiples of the unitary size. A theoretical distribution was then
computed by convolving a binomial distribution, accounting
for quantal content (number of quanta released), and a
Gaussian distribution, allowing for variations in size of individ-
ual quanta. More precisely, the probability for an EPSP to
contain i quanta follows a binomial distribution:
P ið Þ ¼ Cin  pi  ð1 pÞðniÞ; (1)
in which p is the average probability of release, and n is
the total number of releasable quanta. In the frequency
distribution of EPSP amplitude, successive peaks repre-
sent increasing numbers of quanta. In order to predict
how these events are distributed between different bins in
a histogram, it is necessary to allow for variations in quan-
tal size. To do this, the largest peaks of the histogram
were fitted to a Gaussian curve scaled in width to have a
variance proportional to quantal size, and scaled in height
so that its area corresponded to the predicted number of
events (Del Castillo and Katz, 1954). From the mean (m)
and SD (s ) of the Gaussian curve, the content (f) of each
bin (y) is given by:








s Þ2 : (2)
The SD (s ) of each peak depends on the number of
quanta it contains. It was calculated as follows:
s ¼ i  ffiffiffiffiffiffis 0p ; (3)
with i the number of quanta in the peak, and s0 the SD
of a single quanta. The amplitude of Gaussian distribu-
tion for each peak is scaled to the probability PðiÞ for
that peak (see Eq. 1). The complete theoretical distri-
bution, allowing for variance and peak overlap was
then obtained by pooling the Gaussians for all peaks.
In this way, the theoretical distribution could be super-
imposed on the histogram for direct comparison with
the data.
Endocytosis and exocytosis measurements
We used fluorescent FM dye labeling to monitor synap-
tic vesicle cycling at the larval neuromuscular junction
(Verstreken et al., 2008). Third-instar larvae expressing
mCD8::GFP with or without CG31030 RNAi in motor
neurons under control of the OK371-Gal4 driver, were
dissected in a Ca21-free HL3 saline solution (as de-
scribed above), and incubated for 5min in HL3 solution
supplemented with 90 mM KCl, 1.5 mM CaCl2 and 10 mM
fluorescent FM4-64 dye (Invitrogen, T13320) final con-
centrations. Preparations were then washed with Ca21-
free HL3 saline five times, for 2min each, before being
imaged on a Nikon A1R confocal microscope to mea-
sure the level of dye loading. Then the fillets were incu-
bated for 2min in HL3 solution supplemented with 90
mM KCl and 1.5 mM CaCl2 to allow the dye to be un-
loaded from the synapses. Preparations were then
washed with Ca21-free HL3 saline five times, for 2min
each, before being scanned once again to measure the
level of dye unloading. Images were analyzed using the
Fiji software. The fluorescence signal of the dye was
measured in the synaptic area restricted to the signal of
mCD8::GFP. To obtain the percentage of dye that was
unloaded, the ratio of unloaded/loaded fluorescence in-
tensities was calculated.
Synapsemorphology analysis
Immunostaining was performed as described above in
third-instar larvae using an antibody against Discs Large
(Dlg; DSHB, catalog #4F3 anti-discs large-s, 1:500).
Synaptic boutons were then counted manually on the
ventral longitudinal abdominal muscle 6 of the segment
A3, and their diameter measured in blind on randomized
images using the Fiji software.
Statistical treatment
Statistical analysis was performed with the GraphPad
Prism 6 software. The paired Student’s t test was used
for comparison of two genotypes, while either paired or
unpaired ANOVA, with Dunnett’s post hoc test for multi-
ple comparisons, were used for three genotypes.
Results
Drosophila CG31030 encodes a single protein
structurally similar to VhaAC45
Here, we studied the Drosophila gene CG31030, identi-
fied in FlyBase as a paralog of CG8029/VhaAC45, and as
an ortholog of vertebrate ATP6AP1/AC45 and ATP6AP1L/
AC45RP (Thurmond et al., 2019). In FlyBase, CG31030 is
predicted to produce two different protein isoforms,
CG31030-PA and CG31030-PB, which differ in the
sequence of their C-terminal domain, the last 7 C-ter-
minal amino-acids of CG31030-PA being theoretically
replaced by a different segment of 46 amino-acids in
CG31030-PB. We first investigated the existence of
these two isoforms. Using primers framing the 55 bp
difference between the predicted CG31030-RA and
CG31030-RB transcripts (Fig. 1A), which encode CG31030-
PA and CG31030-PB, respectively, we checked which
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isoform was present in Drosophila heads. Only a frag-
ment with the size expected for CG31030-RA was
amplified (Fig. 1B), suggesting that CG31030-PB is
not expressed in this tissue. Consistent with this, PCR
experiments using CG31030-RB-specific primers did
not amplify any cDNA fragment, contrary to experi-
ments using CG31030-RA-specific primers (Fig. 1B).
Moreover, among the numerous cDNA clones match-
ing CG31030 listed in FlyBase, either fully sequenced
or only sequenced at the end (ESTs), most of which
complement both isoforms, several were found to
be specific to CG31030-RA. In contrast, none speci-
fically corresponded to CG31030-RB, supporting the
hypothesis that among the two predicted protein isoforms,
only CG31030-PA is actually expressed in Drosophila.
Therefore, we referred to CG31030-PA simply as CG31030
in the present study.
CG31030 and VhaAC45 share 69.9% similarity in
amino-acid sequences. Like its paralog, CG31030 is
also classified in the V-ATPase family group by the
InterPro database (accession Q8IMJ0_DROME; Mitchell
et al., 2019). They both have a transmembrane domain,
as well as predicted N-glycosylation sites (Fig. 1C). They
also present a pair of conserved cysteine residues typi-
cal of proteins from the AC45 family. Unlike Drosophila
VhaAC45 and vertebrate ATP6AP1/AC45, CG31030
does not possess a potential furin cleavage site (Fig. 1C),
similarly to vertebrate ATP6AP1L/AC45RP and Xenopus
AC45LP (Jansen et al., 2010, 2021).
Using the CRISPR-Cas9 technology, we inserted a small
V5 epitope tag in frame at the 39 end of the CG31030 gene,
thus disrupting the stop codon, to generate the CG31030V5
mutant line (Fig. 1D). A Western blotting on head extracts of
CG31030V5 and control flies was then performed to
Figure 1. Structure of CG31030 compared with its paralog VhaAC45 and construction of CG31030V5. A, Localization of the primers
used for RT-PCR analysis of the two predicted CG31030 transcripts (CG31030-RA and CG31030-RB) in Drosophila heads. B,
Primers detecting both CG31030-RA (F1-R1, expected amplicon size 288bp) and CG31030-RB (F1-R1, expected amplicon size
233bp) only amplify a band corresponding to CG31030-RA (lane 1). CG31030-RA-specific primers (F2-R2) also amplify a fragment
of the expected size (485bp, lane 2), whereas CG31030-RB-specific primers (F3-R3) did not amplify any cDNA fragment (lane 3). C,
VhaAC45 and CG31030 both have a signal peptide (SP; orange bars), a transmembrane domain (TM; blue bars) and predicted N-
glycosylation sites according to NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/; green diamonds). They also present the pair
of cysteine residues characteristic of the AC45 family (red triangles). In addition, VhaAC45 has a predicted furin cleavage site (yellow
bar) which is absent in CG31030 according to ProP 1.0 (http://www.cbs.dtu.dk/services/ProP/). D, Construction of the CG31030V5
mutant strain. A 14-amino acid V5 tag (in red) was fused to the C-terminal end of the CG31030 protein by inserting the V5 coding
sequence ended by a new stop codon (in blue) in place of the original stop codon (in green) in the CG31030 gene using the
CRISPR-Cas9 technology. E, A Western blotting probed with anti-V5 antibody detected two protein bands at an apparent molecular
weight of ;32 kDa in head extracts of CG31030V5 flies (lane 2) and none in the w1118 control sample (lane 1).
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determine the apparent size of the tagged protein. Two dis-
tinct bands, close to each other, were detected specifically in
the CG31030V5 sample, consistent with the presence of gly-
cosylated and unglycosylated forms of the same protein (Fig.
1E). While the predicted size of CG31030-V5 is 44 kDa, the
observed bands corresponded to a size of ;32 kDa. This
could indicate that the protein is actually cleaved, like its pa-
ralog VhaAC45, despite the absence of a predicted cleavage
site (Fig. 1C). However, it is known that membrane proteins
migrate faster on SDS gels, leading to an underestimation of
their size (Rath et al., 2009). This could also explain the small-
er than expected apparent size of CG31030-V5 on Western
blotting.
CG31030 is specifically expressed in neurons and
addressed to synaptic areas
According to FlyAtlas (Chintapalli et al., 2007), VhaAC45
is expressed ubiquitously in Drosophila tissues. In contrast
and interestingly, CG31030 seems to be specifically ex-
pressed in the nervous system in both larval and adult flies,
making it a possible candidate for specific regulation of neu-
ronal V-ATPase (Fig. 2A). To confirm this prediction, we
checked by RT-qPCR the repartition ofCG31030 transcripts
in three parts of the fly body: the head and thorax, which
contains the brain and ventral nerve cord (VNC), respec-
tively, and the abdomen, which is relatively poor in nervous
Figure 2. CG31030 is expressed specifically in neurons. A, Diagram representing expression levels of CG31030 and
VhaAC45 in different tissues relative to the whole fly, according to FlyAtlas data (Chintapalli et al., 2007). CG31030 appears
to be markedly enriched in the nervous system of larva and adult fly, whereas in contrast VhaAC45 seems to be uniformly ex-
pressed in all tissues in these two stages. B, In both males and females, CG31030 mRNA abundance follows the localization
of the CNS (shown in blue on the fly sketch), with the highest expression in the head. Br, brain; VNC, ventral nerve cord.
Results of three independent experiments. C, Knock-down of CG31030 expression in neurons decreases adult longevity.
Pan-neuronal expression of CG31030RNAi3 and Dcr-2 with the elav-Gal4 driver led to a marked shortening of the lifespan of
adult flies. Experiment conducted with 105–110 females per genotype. D, Expression of CG31030RNAi3 with Dcr-2 in all neu-
rons using elav-Gal4 decreased CG31030 mRNA level in head by .80%, while expression of the RNAi construct and Dcr-2 in
all adult glial cells with repo-Gal4 had not effect. Results of three independent experiments. Mean values with SD are re-
ported on the graphs.
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tissue. Both females and males showed highest expression
in the head, minor expression in the thorax and no detecta-
ble expression in the abdomen (Fig. 2B). The expression of
CG31030 therefore closely follows the repartition of the
nervous system in adult flies.
The single-cell RNA-Seq Scope database (Davie et al.,
2018) furthermore indicated that, in Drosophila, CG31030
is expressed in all neurons, with few or no expression in
glial cells. To verify this, we expressed three different
CG31030 RNAi with either the pan-neuronal driver elav-
Gal4 or the pan-glial driver repo-Gal4 (see Table 1 for ge-
notypes of the different Drosophila lines used in this study).
The expression of CG31030RNAi1 and CG31030RNAi2 was
found to be lethal at embryonic and first larval stages, re-
spectively, while CG31030RNAi3 produced viable adults with
a shortened lifespan (Fig. 2C), and obvious locomotor im-
pairments. This difference in phenotypes observed with
different RNAi constructs could be attributed to a varia-
tion in residual levels of the CG31030 protein. RT-qPCR
experiments showed that the pan-neuronal expression
of CG31030RNAi3 together with the RNAi booster Dicer-2
(Dcr-2) was sufficient to decrease by .80% CG31030
transcripts abundance in extracts from the adult heads
(Fig. 2D). On the other hand, glial expression of this RNAi
construct with repo-gal4 had no significant effects on
CG31030 transcript level (Fig. 2D), confirming that this
gene is selectively expressed in neurons. It is interesting
to note that both CG31030RNAi1 and CG31030RNAi2 also
induced lethal phenotypes at various developmental
stages when expressed either with a glutamatergic
(VGlut-Gal4) or a cholinergic (Cha-Gal4) neuronal driver
(data not shown), in accordance with the RNA-Seq data
of the Scope website suggesting a pan-neuronal expres-
sion of this gene.
To validate these observations, we placed the available
MIMIC allele CG31030MI107 that contains a stop codon in-
serted in the middle of the gene (Nagarkar-Jaiswal et al.,
2015) over the deficiency Df(3R)Exel6214 encompassing
CG31030 (Parks et al., 2004). The resulting mutant, likely
to be a null, was found to be embryonic lethal, in agree-
ment with the results obtained with two CG31030 RNAi
lines. Remarkably, re-expressing the gene selectively in
neurons, using a UAS-CG31030 construct driven by elav-
Gal4, was sufficient to rescue this lethality, producing
viable and fertile adults with no obvious behavioral de-
fects (Table 2). These results convincingly indicate that
CG31030 is an essential gene whose expression appears
to be specifically required in neurons.
Next, we studied the cellular localization of this protein
by performing immunostaining on CG31030V5 flies with
an anti-V5 tag antibody. We observed that the general ex-
pression pattern of CG31030 in adult brain (Fig. 3A) and
larval CNS (Fig. 3B) was widespread in the neuropile and
quite similar to that of the synaptic marker CadN, consist-
ent with a predominantly synaptic localization. No specific
signal was detected in a control w1118 line that does not
contain the V5-tagged protein (Fig. 3C). Neuronal cell
bodies were also faintly marked with the V5 antibody in
the CG31030V5 line, both in adult and larva, and a few of
them displayed a signal intensity comparable to that of
the synaptic areas (Fig. 3A,B, arrowheads). The synapse-
containing neuropile areas (like the antennal lobes) were
not as sharply defined as with the CadN antibody, sug-
gesting that axons, like most cell bodies, also contains
low levels of CG31030. Finally, co-immunostaining of
larval body muscles wall with anti-horseradish peroxi-
dase (HRP) antibodies, a marker of Drosophila neurons
(Jan and Jan, 1982), showed precise co-localization with
the V5 signal, indicating that CG31030 is addressed to
synaptic boutons at the larval neuromuscular junction
(Fig. 3D). The lack of V5 immunostaining at the neuro-
muscular junction of control w1118 flies is shown below in
Figure 4D.
CG31030 co-immunoprecipitates with V-ATPase
subunits of the V0 domain
The CG31030 protein is predicted to be part of the
InterPro V-ATPase family, but no experimental informa-
tion is currently available regarding its potential interac-
tors. To determine whether CG31030 could interact,
directly or indirectly, with subunits of the V-ATPase com-
plex, we conducted co-immunoprecipitation experiments
using a V5 antibody on proteins extracted from heads of
CG31030V5 mutants and w1118 control flies, followed by
nano LC-MS/MS analysis of the precipitated proteins.
Three independent experiments were performed to in-
crease reliability, and in total, 410 proteins were identified
in all three experiments. Among those, only 12 proteins
had at least a 2-fold abundance difference with the con-
trol in all three experiments (Fig. 4A; Table 3), one of them
being, as expected, the co-immunoprecipitation target
CG31030-V5. Remarkably, three of the other proteins
were identified as subunits of the V-ATPase complex:
Vha100-1, VhaAC39-1, and ATP6AP2 (Fig. 4B).
Table 2: Pan-neuronal expression of CG31030 rescues the embryonic lethality of CG31030-deficient flies up to the adult
stage
Genotype of the progeny flies1 Expected percentage2 Scored percentage3
Heterozygous deficiency without CG31030 expression 40 39.7
Heterozygous deficiency with pan-neuronal CG31030 expression 40 53.8
Homozygous deficiency without CG31030 expression 0 0
Homozygous deficiency with pan-neuronal CG31030 expression 20 6.4
1Rescue of embryonic lethality was assayed by crossing elav-Gal4; CG31030MI107/TM6B(Tb) females with w; UAS-CG31030/CyO; Df(3R)Exel6214/TM6B(Tb)
males, and scoring the relative number of CG31030-expressing adult flies homozygous for CG31030 deficiency (i.e., non-Tb and non-Cy elav-Gal4/1; UAS-
CG31030/1; CG31030MI107/Df(3R)Exel6214) in the progeny (highlighted line).
2 Expected percentage of adult progeny flies of each genotype in case of full rescue.
3 Actual percentage obtained in the experiments. 24 rescued adults were recovered out of a total of 373 progeny flies.
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Vha100-1 and VhaAC39-1 code for subunits a and d of
the V0 domain, respectively (Vasanthakumar and Rubinstein,
2020). The subunit a is encoded by five different genes in
Drosophila and constitutes the proton port of the pump
(Collins and Forgac, 2020). Among these five isoforms,
Vha100-1 has been shown to be specifically required in neu-
rons and present at the synapse (Hiesinger et al., 2005). Co-
immunostaining experiments confirmed that this protein
colocalizes with CG31030 at the larval neuromuscular junc-
tion (Fig. 4C,D). Subunit d of V0 is encoded by twoDrosophila
genes: VhaAC39-1 and VhaAC39-2, and only the first co-im-
munoprecipitated with CG31030. According to FlyAtlas,
VhaAC39-1 is expressed in many tissues and enriched in the
brain, while VhaAC39-2 seems to be mostly found in testis
and salivary glands. For both V0 subunits, CG31030 thus co-
precipitated with the likely neuronal isoform. The co-immuno-
precipitated V-ATPase subunit which appeared to be the
most enriched in the CG31030V5 sample was, interestingly,
the accessory subunit ATP6AP2, suggesting a possible direct
interaction between this protein and CG31030 (Table 3).
These experiments therefore reinforce the hypothesis that
CG31030 directly interacts with the neuronal V-ATPase com-
plex, and more specifically with V0 since all detected partners
belong, or interact, with this domain.
Similarly, the mouse protein ATP6AP1L/AC45RP, a ver-
tebrate homolog of CG31030, has recently been shown to
interact selectively with V0 domain subunits of the neuronal
V-ATPase (Jansen et al., 2021). In addition, these authors
showed that strong in vitro upregulation (;7-fold) of this
gene resulted in an increased transcript level of some V0
subunit, while a moderate one (;2.6-fold) had no effect ex-
cept on ATP6AP2. We thus wondered whether CG31030
upregulation or downregulation could affect V0 subunit ex-
pression in vivo. Using a pan-neuronal driver, we were able
to increase CG31030 transcript levels, but only up to;3.5-
fold in an in vivo wild-type context, suggesting that tran-
script abundance is regulated posttranscriptionally. This
moderate upregulation did not induce any significant
Figure 3. CG31030 is addressed to synaptic areas. A, B, Anti-V5 immunostaining in the CG31030V5 strain revealed that CG31030 is
mainly addressed to synaptic areas in the adult brain (A) and larval CNS (B), as indicated by its colocalization with the presynaptic
marker CadN. Green fluorescence outside synaptic areas reveal that cell bodies are also faintly marked by the V5 antibody, with a
few of them showing a bright signal (arrowheads). OL, optic lobe; AL, antennal lobe; SO, subesophageal ganglion. C, CadN and V5
immunostaining of adult brain (left panels) and larval CNS (right panels) from w1118 control flies. No signal was detected with the
anti-V5 antibody in the absence of V5-tagged protein. D, Anti-V5 antibody also labels the neuromuscular junction of CG31030V5 lar-
vae, where it co-localizes with anti-HRP immunostaining that specifically marks neuronal membranes, confirming CG31030 synaptic
localization. Scale bars: 100 mm (A–C) and 10mm (D).
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changes in transcript levels of V0 subunits, but possibly
it was not sufficient to see such effects (Fig. 5A).
Conversely, we performed RT-qPCR experiments on ex-
tracts from Drosophila heads expressing CG31030RNAi3
in all neurons compared with controls, and here again,
we could not find any significant change in V0 subunit ex-
pression level in knock-down context (Fig. 5B). Notably,
VhaAC45 is expressed at a similar level in CG31030
knock-down flies and in controls. The homology be-
tween CG31030 and VhaAC45 could raise the question
of a potential functional redundancy of the two proteins.
However, the lethal phenotype and the highly reduced
longevity occurring when CG31030RNAi.1/2 or CG31030RNAi.3
are expressed in all neurons, respectively, suggest that
VhaAC45, though still present, is unable to substitute
for CG31030.
CG31030 knock-down impairs synaptic vesicle
acidification
Because CG31030 appeared to be mainly localized in
synaptic areas, we chose to look at the physiological ef-
fect of its disruption at the Drosophila larval neuromuscu-
lar junction, a model that has contributed to elucidate
many essential synaptic processes. At synaptic nerve
endings, a prominent role of the V-ATPase is to acidify
the lumen of synaptic vesicles, the electrochemical
gradient generated providing the driving force to load
Figure 4. CG31030 co-immunoprecipitates with V-ATPase subunits. A, Scatter plot of proteins identified by nano LC-MS/MS in
three independent co-immunoprecipitation experiments using anti-V5 antibodies. R1, R2 and R3 represent the abundance ratio of
proteins identified in adult head extracts from CG31030V5 over w1118 control in experiments 1, 2 and 3, respectively. Log2(R) = 1 cor-
responds to a 2-fold abundance difference. A total of 12 proteins were found to be at least twice as abundant in CG31030V5 as in
the control in all three experiments (red or blue dots on the graph). One of them is the immunoprecipitation target CG31030 (yellow
dot) and three of these proteins belong to the V-ATPase complex (red dots). A list of these 12 proteins with their Log2(R) values is
provided in Table 3. B, Standard model of the Drosophila V-ATPase complex showing structure of the V1 and V0 domains and the
predicted localization of the three subunits that co-immunoprecipitated with CG31030. C, Co-localization of CG31030-V5 with
Vha100-1 at the larval neuromuscular junction. Larval muscles were labeled with an anti-HRP antibody to mark neuronal mem-
branes. CG31030 has a similar localization to that of Vha100-1, the synaptic isoform of subunit a of the V0 domain. D, In w
1118 con-
trol flies, no specific signal could be detected at the neuromuscular junction with the anti-V5 antibody. Scale bars: 10 mm (C, D).
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and concentrate the neurotransmitters. Thus, a mal-
function of synaptic V-ATPase should induce a decrease of
neurotransmitter concentration inside the vesicles, poten-
tially resulting in an altered synaptic transmission. To test
this hypothesis, we co-expressed each of the two strong-
est CG31030 RNAi constructs together with VMAT-
pHluorin, a pH-sensitive probe targeted to synaptic
vesicles (Wu et al., 2013), in larval motoneurons using the
glutamatergic driver OK371-Gal4. Both RNAi1 and RNAi2
induced a lethal phenotype at pupal stage in these condi-
tions. VMAT-pHluorin is an ecliptic pHluorin that is fluores-
cent at neutral pH, and gets quenched, by protonation, at
Table 3: List of the genes encoding proteins that co-immunoprecipitated with CG31030 in Drosophila head extracts
Gene symbol1 FlyBase gene ID Log2(R1) Log2(R2) Log2(R3)
ATP6AP2 FBgn0037671 6.154281057 9.481786693 5.17436482
Vha100-1 FBgn0028671 1.499248537 8.012982519 5.43599503
VhaAC39-1 FBgn0028665 2.104797507 8.293264658 4.86741949
CG31030 FBgn0051030 3.669278876 7.960835791 5,19465574
Twdlb FBgn0033658 1.642952792 3.068640973 2.35207192
Ccp84Ag FBgn0004777 1.543972087 1.326485589 1.86392045
CG13627 FBgn0039217 5.738384187 4.008318188 3.18433108
mfas FBgn0260745 1.596554441 3.368384477 3.03376685
CG16820 FBgn0032495 4.77051909 9.784086057 3.60280541
Cpr64Ab FBgn0035511 1.08994458 2.758609792 2.31103817
CG14752 FBgn0033307 2.21698759 3.69458382 3.10154816
CG15615 FBgn0034159 2.77101281 5.12362053 3.39808341
1 12 proteins were identified with at least twice higher abundance in CG31030V5 flies compared to the w1118 control in three independent co-immunoprecipitation
experiments with anti-V5 antibodies, followed by mass spectrometry analysis. Among these proteins, three are known to be constitutive or accessory subunits of
the V-ATPase complex: ATP6AP2, Vha100-1 and VhaAC39-1.
Figure 5. Change in CG31030 expression does not alter V-ATPase subunit transcript levels. A, B, CG31030 upregulation (A) or
knock-down (B) in vivo did not significantly affect adult head transcript levels of several V-ATPase V0 subunits. Results of three inde-
pendent RT-qPCR experiments. Means and SD are displayed on the graph.
Research Article: New Research 12 of 22
September/October 2021, 8(5) ENEURO.0193-21.2021 eNeuro.org
acidic pH (Miesenböck et al., 1998). Thus, in control condi-
tion, VMAT-pHluorin should not be fluorescent in synaptic
vesicles, whose pH is at ;5.5, but only when externalized
on the presynaptic membrane during exocytosis, and so,
in contact with the more neutral synaptic cleft milieu. In the
case of an acidification defect of synaptic vesicles, the
probe could be fluorescent both in synaptic vesicles,
where pH would be abnormally high, and on the presynap-
tic membrane (Fig. 6A, central panel).
In order to evaluate the ratio of the internal fluorescence
(from synaptic vesicles) over the external fluorescence
(from the presynaptic membrane) at the neuromuscular
junction of CG31030 knock-down larvae compared with
controls, we first quenched the external signal by replac-
ing the physiological milieu by an identical one with pH
adjusted to 5.5 (Fig. 6A, left panel). This operation resulted
in only the internal signal being conserved. In controls,
this meant that all signal was abolished, as expected
because the synaptic vesicles were normally acidified
(Fig. 6B, left panel). In contrast and strikingly, a resid-
ual signal was still visible in this acidic milieu in both
RNAi1 and RNAi2 knock-down larvae (Fig. 6B, right
panel). Quantification of the ratio of fluorescence area
in acidic milieu over neutral milieu showed that ;37%
of the total signal remained visible in the RNAi larvae
after external quenching (Fig. 6C,D).
To verify that the residual signal seen in knock-down
larvae was indeed coming from inside vesicles, the oppo-
site strategy was used: instead of quenching the outside
signal, we revealed all the internal one by collapsing the
pH gradient of synaptic vesicles (Fig. 6A, right panel). To
do so, we replaced the physiological milieu by an ammo-
nium solution, as previously described (Poskanzer and
Davis, 2004). This solution had the same composition ex-
cept that 50 mM NaCl were replaced by 50 mM NH4Cl.
Ammonium and ammonia being in equilibrium (NH4
1 ⇄
NH3 1 H
1), uncharged ammonia crosses membranes and
binds to protons leading to an alkalization of vesicle
lumen pH. This increase of vesicular pH is maintained dur-
ing NH4Cl exposure. In control condition, this gradient
collapse should reveal the VMAT-pHluorin probe present
in synaptic vesicles and thus highly increase the fluores-
cent signal. On the contrary, in the case of an acidification
defect, the signal should remain fairly stable since syn-
aptic vesicles are already fluorescent. Results were
consistent with this hypothesis: while the fluorescence
of controls increased ;3-fold in the pH collapsing am-
monium solution, the signal in CG31030 knock-down
larvae hardly rose by 10–20% depending on the RNAi
construct (Fig. 6E–G). Taken together, these results in-
dicate that CG31030 knock-down significantly de-
creases protons concentration in synaptic vesicles of
motoneuron terminals.
CG31030 downregulation decreases larval locomotor
performance
A reduced pH gradient of synaptic vesicles in larval
motoneurons could alter synaptic transmission and, conse-
quently, the larval locomotor behavior. To assess locomotion,
we recorded the spontaneous crawling of third-instar larvae
expressing CG31030 RNAi1 or RNAi2 in motoneurons with
OK371-Gal4 on an agar plate with no food source for 2 min
periods. We first checked that the average length and width
of knock-down larvae were not significantly different from
those of control larvae (Fig. 7A). Tracking was then performed
using the FIMtrack software (Risse et al., 2014), allowing
measurement of the total distance traveled and of the stride
size, defined as the distance crawled during one peristaltic
wave of muscle contraction, and duration (Fig. 7B). The
knock-down larvae obviously moved less than controls on
the plate, as confirmed by their trajectorymaps (Fig. 7C), trav-
eling a distance only half as long as controls with both RNAi
(Fig. 7D).
In contrast, the stride size actually showed little or no
difference, depending on the RNAi, between knock-down
larvae and controls (Fig. 7E). Instead, we found that the
stride duration, which is the time necessary to accomplish
one peristaltic wave, was significantly longer in knock-
down animals compared with controls for both RNAi (Fig.
7F). These results suggest that the knock-down larvae
may need about twice as much time as controls to reach
the required level of muscular contraction to accomplish
one stride. This could be a compensatory mechanism to
adapt to a lower amount of neurotransmitter released in
response to motor nerve stimulation, as would be ex-
pected if the synaptic vesicles were less filled in CG31030
knock-down context.
Quantal size is reduced in CG31030 knock-down
larvae
The locomotor deficit of CG31030 knock-down larvae
could originate from an impairment of synaptic transmis-
sion at the neuromuscular junction or a defect in the central
control of motor behavior, or both. Fluorescent FM-dye
loading/unloading experiments can be used to monitor po-
tential defects in endocytosis or exocytosis of synaptic
vesicles at the larval neuromuscular junction (Verstreken et
al., 2008). We therefore assessed whether the synaptic vesi-
cle cycle induced by KCl stimulation was affected by
CG31030 downregulation, as this could well have an impact
on neurotransmission and locomotion. Representative im-
ages of neuromuscular junctions from control and knock-
down larvae after FM-dye loading and unloading are shown
in Figure 8A,B, respectively. The larvae expressing
CG31030 RNAi1 or RNAi2 in motoneurons, were apparently
able to load and unload the dye in synaptic junctions simi-
larly as controls (Fig. 8C,D). The percentage of previously
loaded FM4-64 dye released during the unloading phase
was also comparable for control and knock-down larvae
(Fig. 8E,F). This result indicates that the synaptic vesicle
cycle, and in particular the exocytosis machinery, were ap-
parently not impacted byCG31030 inactivation.
To determine whether neurotransmission was other-
wise affected by CG31030 knock-down, we conducted
electrophysiological recordings to measure the quantal
size, which is the postsynaptic response to the release of
one synaptic vesicle. We expressed CG31030 RNAi1 or
RNAi2 in motoneurons of third-instar larvae with the
OK371-Gal4 driver, and recorded spontaneous mEPSPs
intracellularly from ventral longitudinal abdominal muscle
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Figure 6. CG31030 knock-down larvae have a synaptic vesicle acidification defect. A, Schematic representation of the protocols
used to assess relative acidity levels of synaptic vesicles at the larval neuromuscular junction. Top center diagram, In control condi-
tions, fluorescence can be emitted by VMAT-pHluorin in the presynaptic membrane but not in synaptic vesicles since their lumen is
acidified. In case of defective synaptic vesicle acidification, both the presynaptic membrane and synaptic vesicles should emit fluo-
rescence. Left diagram, The fluorescence emitted by VMAT-pHluorin in the presynaptic membrane can be quenched by replacing
the extracellular medium with an acidic HL3 solution. This quenching should result in an almost complete extinction of the signal in
control flies, in which synaptic vesicles are normally acidified, while a residual signal is expected to be visible in flies having a synap-
tic vesicle acidification defect. Right diagram, Replacement of 50 mM NaCl by 50 mM NH4Cl in the neutral HL3 solution should lead
to a collapse of the pH gradients because of the free diffusion of NH3 in membranes, so that fluorescence will be emitted both by
the presynaptic membrane and synaptic vesicles both in control and mutant conditions. B, Representative pictures showing the ef-
fect of perfusing an acidic HL3 solution on VMAT-pHluorin fluorescence in control and CG31030 knock-down larvae. C, D,
Quantification of the ratio of the fluorescence level at pH 5.5 over the original signal at pH 7.6. Whereas the low pH extinguished flu-
orescence in control flies, ;37% of the signal persisted after quenching in CG31030 knock-down larvae using two different RNAi
constructs. E, Representative pictures showing the effect of collapsing the synaptic vesicle pH by perfusing HL3-NH4Cl in control
and CG31030 knock-down larvae. F, G, Quantification of the ratio of the signal in HL3-NH4Cl over the original signal in HL3 showed
that fluorescence increased ;3-fold in controls while it only rose by 10–20% depending on the RNAi in CG31030 knock-down lar-
vae. Results of four independent experiments, with three to five larvae analyzed per genotype in each experiment. Unpaired Student’s
t test; *p, 0.05, ***p, 0.001. Mean values with 95% confidence intervals are reported on the graphs. Scale bar: 15mm (B).
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6 of segment A3 (Fig. 9A). These muscles are innervated
by synaptic boutons that are clearly marked by OK371-
Gal4, as shown by the co-localization of membrane-asso-
ciated GFP and the postsynaptic marker Dlg in OK371.
mCD8::GFP flies (Fig. 9B). Representative amplitude dis-
tributions of mEPSPs in a control and RNAi1 larvae are
shown in Figure 9C. Quantal analysis of recorded
events confirmed that both RNAi1 and RNAi2 knock-
down larvae have a significantly reduced quantal size
compared with controls (Fig. 9D), suggesting a de-
crease in glutamate vesicular uptake, and potentially
linking vesicle acidification defect and locomotor im-
pairment. The V-ATPase dysfunction in synapses of
CG31030 knock-down larvae could apparently lead to
incomplete loading of vesicles, thus decreasing the
amount of neurotransmitter released per unit of time
during a peristaltic wave, and potentially slowing down
larval locomotion. Although the mean frequency of
mEPSPs of both RNAi1 and RNAi2 larvae appeared
lower than controls, this effect was not statistically
significant (Fig. 9E). This may suggest that CG31030
knock-down did not significantly increase the number
of unacidified vesicles empty of neurotransmitter.
Finally, we also looked at the morphology of the neu-
romuscular junctions in CG31030 knock-down and
control animals by measuring the number and diame-
ter of synaptic boutons innervating the ventral longit-
udinal abdominal muscle 6 in the segment A3. The
overall number and mean size of boutons were not sig-
nificantly affected between the different genotypes
(Fig. 10A–D). However, we observed that knock-down
larvae exhibited a reduced number of boutons with a
Figure 7. CG31030 downregulation in motoneurons decreases larval locomotor performance. A, CG31030 knock-down in moto-
neurons did not significantly alter larval size. Larval length is defined as the spine length from head to tail, while larval width is the di-
ameter of the mid-spine circle. Average larval length and width were not significantly different between animals expressing
CG31030 RNAi1 (left panels) and RNAi2 (right panels) in motoneurons and controls. B, Schematic representation of the successive
phases of larval locomotion. Stride size is defined as the distance crawled during one peristaltic wave of muscle contraction, while
stride duration is the time necessary for the completion of one peristaltic wave. C, Locomotor trails of individual larvae recorded
over a period of 2min. Larvae expressing CG31030 RNAi in motoneurons show reduced spontaneous movements (middle panel)
compared with the driver (left panel) and effector (right panel) controls, respectively. Scale bar: 25 mm. D, Quantification of the trav-
eled distances confirmed that knocking down CG31030 in motoneurons with two different RNAi induced significant locomotor de-
fects. E, F, Stride size (E) appears to be less affected than stride duration (F) in the knocked-down larvae. Result of five
independent experiments, with three to four larvae analyzed per genotype in each experiment. One-way ANOVA with Dunnett’s
post hoc test for multiple comparisons; **p, 0.01, ***p, 0,001. Mean values with 95% confidence intervals are reported on the
graphs.
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diameter superior to 4 mm for both RNAi1 and RNAi2
(Fig. 10E,F). The fact that these large boutons only rep-
resented a small fraction of the total explains why the
average number or mean diameter of boutons were not
altered in knock-down larvae. It is therefore unlikely that
this size variation could result, by itself, in the significant
decrease in quantal size and strong locomotor impair-
ment induced by CG31030 downregulation. Neuronal
activity is known to influence synaptic growth at the
neuromuscular junction (Menon et al., 2013), so the lower
number of larger boutons in knock-down animals could be
a consequence of the impaired synaptic transmission re-
sulting from the quantal size decrease. Alternatively, the
lower number of high diameter boutons could also be a
modest contributor to the observed quantal size decrease,
as larger boutons have been shown to harbor bigger syn-
aptic vesicles associated with higher quantal content
(Karunanithi et al., 2002).
Figure 8. Lack of effect of CG31030 knock-down on the synaptic vesicle cycle at the larval neuromuscular junction. A, B,
Representative images of mCD8::GFP-labeled neuromuscular junctions of a control (A) and a knock-down (B) larva after loading
and unloading of the fluorescent FM4-64 dye. C, D, Nerve terminals from larvae expressing CG31030 RNAi1 (C) or RNAi2 (D) were
able to both load and unload the fluorescent FM4-64 dye as efficiently as controls. No significant difference was observed between
controls and knock-down animals during the loading and the unloading phases. Fluorescence was normalized relative to the level in con-
trol larva synapses after 5-min loading. E, F, The percentage of previously loaded FM4-64 dye released during the unloading phase was
similar for control and knock-down larvae when using either RNAi1 (E) or RNAi2 (F); **p , 0.01, ***p 0.001, ns: not significant.
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Figure 9. Synaptic quanta size is reduced in CG31030 knock-down larvae. A, Schematic representation of a dissected larval fillet.
Spontaneous miniature EPSPs (mEPSPs) were recorded intracellularly from the ventral longitudinal abdominal muscle 6 in segment
A3. B, Expression of membrane-associated mCD8::GFP with the glutamatergic driver OK371-Gal4 strongly labels the presynaptic
nerve endings at the neuromuscular junction of muscles 6–7 in segment A3. The scaffolding protein Dlg was used as a postsynaptic
marker. Scale bar: 20 mm. C, Representative distributions of spontaneous mEPSPs recorded in a control larva (top panel, in gray)
and a CG31030 RNAi knock-down larva (bottom panel, in orange). The dotted lines represent actually recorded amplitudes and the
plain lines the computed theoretical distributions. Genotypes and quantal size (q) are indicated on each graph. D, Quantal analysis
of recorded events showed that knock-down larvae have a significantly reduced synaptic quanta size compared with controls, both
with CG31030 RNAi1 (top panel, in orange) or RNAi2 (bottom panel, in blue). E, Although both RNAi1 (left panel) and RNAi2 (right
panel) larvae had a lower mean EPSP frequency than controls, this difference was not statistically significant. Six to seven cells re-
corded per genotype. One-way ANOVA with Dunnett’s post hoc test for multiple comparisons; *p, 0.05, **p, 0.01, ***p, 0.001.
Mean values with 95% confidence intervals are reported on the graphs.
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Discussion
In this study, we investigated the hypothesis that the
previously uncharacterized Drosophila protein CG31030 is
a specific regulator of the neuronal V-ATPase. At var-
iance with its broadly expressed paralog VhaAC45, we
have shown that CG31030 is found mainly, if not only,
in neurons. We also provide evidence that CG31030 in-
teracts with two constitutive subunits and one acces-
sory subunit of the V-ATPase, the constitutive ones
being also enriched in neurons, and that it is required to
have properly acidified synaptic vesicles. This implies
that CG31030 is an essential protein for nervous system
functioning in Drosophila.
CG31030 is an essential synaptic protein
In yeast, all V-ATPase subunits are coded by a single
gene, with the exception of the V0 subunit a. The knock-
out of any of the single-gene subunits all present a similar
phenotype: the inability to survive in a neutral pH environ-
ment (Nelson, 2003). For subunit a, the same phenotype
was only achieved in a double-mutant of both isoforms
(Manolson et al., 1994). In multicellular organisms,
Figure 10. Effect of CG31030 knock-down on synapse morphology at the larval neuromuscular junction. A–D, No significant differ-
ence was observed in the mean synaptic bouton diameter (A, B) or the average number of boutons per synapse (C, D) between lar-
vae expressing CG31030 RNAi1 (A, C) or RNAi2 (B, D) in motoneurons and the controls. E, F, Knock-down larvae showed a smaller
percentage of boutons with a diameter larger than 4 mm for both RNAi1 [E; but not significant (ns) compared with the effector con-
trol] and RNAi2 (F), n=6–8 synapses per genotype, two-way ANOVA with Dunnett’s correction for multiple comparisons; *p , 0.05,
**p , 0.01, ***p , 0.001, ns: not significant.
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mutations of V-ATPase subunits, or accessory proteins, also
often lead to a lethal phenotype at various developmental
stages, whether in mice (Inoue et al., 1999; Sun-Wada et
al., 2000; Schoonderwoert and Martens, 2002b),
Caenorhabditis elegans (Lee et al., 2010), or flies (Davies et
al., 1996; Allan et al., 2005). Similarly, we found a CG31030
null mutant to be embryonic lethal, and, interestingly, this
lethality could be rescued to the adult stage by re-express-
ing CG31030 in all neurons, showing that the protein is
specifically required in this cell type for fly survival. The per-
centage of adult survivors was about three times less than
what would be expected in case of a full rescue (Table 2)
and the missing two-thirds likely died at an early develop-
mental stage as no larval lethality was observed. This could
be explained by the fact that CG31030 protein re-expres-
sion in rescued knock-out flies first required the expression
of Gal4 under regulation of the elav promoter, which starts
to express rather late in embryos, followed by activation of
the UAS sequence upstream the CG31030 insert. So, it is
possible that part of the mutant embryos did not survive
the delay inherent to this ectopic expression process.
We observed that CG31030 transcripts follows the re-
partition of the nervous system, with the highest relative
abundance in the head. Moreover, pan-neuronal expres-
sion of CG31030RNAi3, the RNAi construct with the weak-
est effect on fly survival, was sufficient to decrease by
.80% its level in the brain of adult escapers. These re-
sults indicate that CG31030 expression is mainly neuro-
nal, if not even entirely restricted to neurons. In addition,
CG31030 cellular localization shows similarity with a syn-
aptic pattern. Cell bodies were also marked, although
generally less strongly. Synaptic protein complexes can
be assembled in the cell bodies before being transported
in axons, and it is the case for the soluble and membrane-
bound domains of synaptic V-ATPase, as was shown in
Torpedo (Morel et al., 1998). It is difficult to decide
whether the signal coming from cell bodies corresponds
to a functional site for CG31030 or rather to newly pro-
duced proteins that have not yet been targeted to synap-
ses. However, the prominent signal in synaptic areas led
us to assume that CG31030 plays an important role in the
synaptic process.
CG31030 is required for proper synaptic vesicle
acidification
In presynaptic terminals, the most abundant organelles
are synaptic vesicles, which require acidification to pro-
vide the driving force for neurotransmitter loading. This
acidification is ensured by the V-ATPase pump, which
generates an electrochemical gradient by importing pro-
tons into the vesicle lumen, thus creating both a mem-
brane potential (DW, inside positive voltage) and a pH
gradient (DpH, acidic lumen). Our experiments showed
that the knock-down of CG31030 at the glutamatergic
larval neuromuscular junction increased the internal pH of
synaptic vesicles, and so decreased the DpH component
of the electrochemical gradient generated by the V-
ATPase. This result is however by itself insufficient to con-
clude to a dysfunction of the proton pump, since other
players have been shown to influence synaptic vesicle pH
gradient downstream V-ATPase activity. For example,
cation/H1 exchangers, found on synaptic vesicles, can
decrease DpH while increasing DW by exchanging cati-
ons, like Na1 or K1, against luminal H1 (Takamori, 2016).
This activity can be upregulated by increased intracellular
concentration of these cations (Huang and Trussell,
2014). Glutamate being negatively charged, its transport
across vesicular membrane is predominantly driven by
DW (Maycox et al., 1988; Tabb et al., 1992). As a conse-
quence, the increased membrane potential resulting from
upregulation of cation/H1 exchangers actually facilitates
glutamate uptake (Goh et al., 2011; Huang and Trussell,
2014). We measured synaptic quanta size by quantal
analysis of mEPSPs of CG31030 knock-down larvae and
found that it was decreased, contrary to what would be ex-
pected in the case of an upregulation of cation/H1 exchang-
er activity. This apparent decrease of vesicular glutamate
concentration was corroborated by its phenotypical conse-
quence, namely the locomotion defect exhibited by knock-
down larvae. This suggests that the observed diminution of
DpH is correlated with a diminution of DW, thus pointing to-
ward a V-ATPase malfunction. This hypothesis is further
supported, physiologically, by the lack of defect in the endo-
cytosis/exocytosis cycling of synaptic vesicles in knock-
down larvae, making it unlikely that such a defect could be
at the origin of the locomotor impairment, and, at themolecu-
lar level, by the co-immunoprecipitation of CG31030 with
three V-ATPase subunits of the V0 domain (Vha100-1,
VhaAC39-1, and ATP6AP2), all of them being associated
with the neuronal V-ATPase. Altogether, these results
strongly suggest that CG31030 is a neuronal protein
necessary for V-ATPase function in synaptic nerve
endings.
Some V-ATPase subunits isoforms in other species
have been shown to target specific subcellular compart-
ments, like the Torpedo V0 a1 isoform which is found in
synaptic V-ATPase and not in neuronal cell bodies (Morel
et al., 2003). Similarly, CG31030 could be specifically in-
volved in the regulation of synaptic V-ATPase, or, alterna-
tively, globally act on all neuronal V-ATPase. Specificity
level could even be pushed further, since synaptic
vesicles are not the only organelles requiring acidification
that are localized in synapses. Thus, a synaptic V-ATPase
regulator could be devoted to synaptic vesicles as it could
be affecting more generally all synaptic V-ATPase com-
plexes, indifferently of their membrane localization. The
answer to such questions could help better understand
regulations of synaptic transmission, since synaptic V-
ATPase activity is one of the presynaptic modulators of
quantal response (Takamori, 2016; Gowrisankaran and
Milosevic, 2020).
CG31030 interacts with ATP6AP2 andmay regulate V-
ATPase domain dynamics
While accessory subunits directly interact with V-
ATPase domains, other stimulus can indirectly affect activ-
ity of the complex, like glucose concentration or serotonin
(Sautin et al., 2005; Voss et al., 2007). Co-precipitation of
CG31030 with V-ATPase subunits does not necessarily
imply a direct interaction, but suggests a minima an
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indirect association with the complex, possibly in a non-
transient manner. The impairment in V-ATPase activity in-
duced by CG31030 downregulation rules out the hypothe-
sis of an inhibitory action of this protein on the proton
pump. Nevertheless, the precise requirement of CG31030
for activity of the V-ATPase complex still remains unknown
to date. Lethality of the mutant could indicate an essential
role of CG31030 in V-ATPase function. However, some V-
ATPase regulators and accessory subunits have been
found in other signaling pathways, like ATP6AP2 in the
renin-angiotensin system (Nguyen, 2010), so we cannot
exclude that lethality could be because of CG31030 play-
ing a part in other vital neuronal functions. Signal in axons
could also point to a role in targeting the complex to the
synapses. The two domains of the V-ATPase, V0 and V1,
are believed to be assembled in cell bodies before being
separately transported to synaptic area, V0 by fast axonal
anterograde transport, most likely directly on new synaptic
vesicles, and V1 by slow axonal transport like other cyto-
plasmic synaptic proteins (Morel et al., 1998). CG31030
could be involved in the transport of one of the two do-
mains, and effects of CG31030 knock-down could then re-
sult from a decreased synaptic abundance of the affected
V-ATPase domain. However, it is believed that only one
copy of the V-ATPase complex is sufficient to properly
acidify one synaptic vesicle (Takamori, 2016), a conse-
quence of this being that neurotransmitter loading would
be an all-or-none process. Consistent with this, mutation
of the Drosophila synaptic V0 subunit Vha100-1 does not
seem to impact quantal size but rather mEPSP fre-
quency, potentially reflecting the presence of an in-
creased number of empty synaptic vesicles (Hiesinger et
al., 2005). Similarly, a reduction in the frequency of spon-
taneous quantal events with no change in quantal size
was observed when the Drosophila vesicular glutamater-
gic transporter (VGlut) was downregulated, also sug-
gesting that a single copy of VGlut is sufficient for proper
loading of a vesicle (Daniels et al., 2006). The fact that
CG31030 knock-down changes the quantal size but not
significantly mEPSP frequency seems to point toward a
role of this accessory protein in V-ATPase efficiency,
rather than in a process affecting the abundance of the
complex such as synaptic targeting.
In this respect, it is interesting to note that the V-
ATPase protein that more consistently co-immunoprecipi-
tated with CG31030 in our experiments is the accessory
subunit ATP6AP2, the fly homolog of human ATP6AP2/
PRR. Interestingly, the vertebrate homolog of CG31030,
ATP6AP1/Ac45, has also been shown to interact with
ATP6AP2, and the complex they form has been proposed
to enable the assembly and disassembly of the catalytic
and membrane domains of the V-ATPase in the mamma-
lian brain (Rujano et al., 2017; Abbas et al., 2020). This
suggests that CG31030 could similarly play a role in the
regulation of these dynamic processes. Indeed, it was
shown that the dissociation of the two V-ATPase domains
on synaptic vesicles is a necessary step before exocyto-
sis (Bodzeôta et al., 2017). When new vesicles are formed
through endocytosis, the two domains then reassemble
to start re-acidifying the vesicular lumen, allowing
neurotransmitter uptake. Thus, during the synaptic
vesicles recycling cycle, V0 and V1 dynamically alternate
between assembled and disassembled states. CG31030
could then be important to facilitate the assembly of the
two domains or maintain the assembled state, which may
also influence neurotransmitter loading and release in a
more continuous way. Our results suggest indeed that
modulating V-ATPase activity in presynaptic terminals
can finely affect quantal size. Whether such regulation ac-
tually occurs in physiological, or pathologic, conditions
remains to be established.
Human ATP6AP2/PRR is known to be a Parkinsonism
candidate gene and its mutations in humans, mice or flies
can lead to cognitive impairment, neurodegeneration and
epilepsy (Korvatska et al., 2013; Dubos et al., 2015;
Ichihara and Yatabe, 2019). It is therefore of major interest
to identify a potential new interactor of ATP6AP2 that is spe-
cific to the nervous system, as it could help better understand
the consequences of V-ATPase dysregulation on synaptic
transmission in pathologic contexts. Accordingly, it would be
very interesting to determine whether human ATP6AP1 and/
or ATP6AP1L share a conserved function with Drosophila
CG31030 in the nervous system. Like CG31030, the mouse
ATP6AP1L/AC45RP was recently reported to be restricted to
neurons (Jansen et al., 2021), and they are, to date, the only
known V-ATPase genes with such tissue specificity. Both
proteins also have the particularity of not having a predicted
furin cleavage site. ATP6AP1L/AC45RP was shown to be in-
volved in neuronal growth (Jansen et al., 2021), while we ob-
served that CG31030 downregulation also decreased the
number of large synaptic boutons at the neuromuscular junc-
tion, hinting at a potential functional homology. Owing to its
structural and functional similarity with its closest
Drosophila homolog, VhaAC45/ATP6AP1, and vertebrates
ATP6AP1L/AC45RP, we propose therefore that CG31030
be named VhaAC45-related protein (VhaAC45RP).
In conclusion, our present work identified a specific reg-
ulator of neuronal V-ATPase in Drosophila that is required
for synaptic vesicle acidification, nervous system func-
tioning and survival. Further study on this protein should
provide a more detailed picture of the complex regulations
surrounding neuronal V-ATPase specificity, revealing po-
tential therapeutic targets and a better understanding of
fundamental processes such as synaptic transmission.
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